08:56 AM EDT, 06/26/2024 (MT Newswires) -- Health care stocks were flat to lower pre-bell Wednesday with the iShares Biotechnology ETF (IBB) inactive and the Health Care Select Sector SPDR Fund (XLV) down 0.01% recently.

Savara (SVRA) rose nearly 21% after saying the phase 3 IMPALA-2 clinical trial assessing the efficacy and safety of Molgramostim in adult patients with autoimmune pulmonary alveolar proteinosis met its primary endpoint.